About Sonoma Biotherapeutics
Sonoma Biotherapeutics is a company based in San Francisco (United States) founded in 2012 by Fred Ramsdell, Qizhi Tang, and Alexander Rudensky.. Sonoma Biotherapeutics has raised $335 million across 3 funding rounds from investors including Fidelity Investments, Lyell Immunopharma and ARE. The company has 74 employees as of December 31, 2021. Sonoma Biotherapeutics offers products and services including Living Cell Therapies and T reg Therapy. Sonoma Biotherapeutics operates in a competitive market with competitors including Jazz Pharmaceuticals, Biogen, Moderna, Celgene and Denali Therapeutics, among others.
- Headquarter San Francisco, United States
- Employees 74 as on 31 Dec, 2021
- Founders Fred Ramsdell, Qizhi Tang, Alexander Rudensky
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Sonoma Biotherapeutics, Inc.
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$335 M (USD)
in 3 rounds
-
Latest Funding Round
$265 M (USD), Series B
Aug 04, 2021
-
Investors
Fidelity Investments
& 21 more
-
Employee Count
74
as on Dec 31, 2021
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Sonoma Biotherapeutics
Sonoma Biotherapeutics offers a comprehensive portfolio of products and services, including Living Cell Therapies and T reg Therapy. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Therapies designed to restore immune balance for autoimmune diseases
Cell-based treatments targeting rheumatoid arthritis and inflammation
Unlock access to complete
Unlock access to complete
Funding Insights of Sonoma Biotherapeutics
Sonoma Biotherapeutics has successfully raised a total of $335M across 3 strategic funding rounds. The most recent funding activity was a Series B round of $265 million completed in August 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 3
- Last Round Series B — $265.0M
-
First Round
First Round
(06 Feb 2020)
- Investors Count 22
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Aug, 2021 | Amount | Series B - Sonoma Biotherapeutics | Valuation | Ally Bridge Group | |
| Sep, 2020 | Amount | Series A - Sonoma Biotherapeutics | Valuation | Lyell Immunopharma , Arch Venture Partners |
|
| Feb, 2020 | Amount | Series A - Sonoma Biotherapeutics | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Sonoma Biotherapeutics
Sonoma Biotherapeutics has secured backing from 22 investors, including venture fund and institutional investors. Prominent investors backing the company include Fidelity Investments, Lyell Immunopharma and ARE. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Private equity and hedge fund investments in healthcare are managed.
|
Founded Year | Domain | Location | |
|
Deep Track Capital is engaged in biotechnology investment activities.
|
Founded Year | Domain | Location | |
|
Investing in Life Sciences sectors like Healthcare and Biotechnology.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Sonoma Biotherapeutics
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Sonoma Biotherapeutics
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Sonoma Biotherapeutics Comparisons
Competitors of Sonoma Biotherapeutics
Sonoma Biotherapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Jazz Pharmaceuticals, Biogen, Moderna, Celgene and Denali Therapeutics, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| domain | founded_year | HQ Location |
Therapies for neurodegenerative and immunology disorders are developed.
|
|
| domain | founded_year | HQ Location |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| domain | founded_year | HQ Location |
Therapies for cancer and inflammatory diseases are developed.
|
|
| domain | founded_year | HQ Location |
Neurodegenerative disease therapies are developed for Alzheimer's, ALS, and Parkinson's.
|
|
| domain | founded_year | HQ Location |
Small-molecule drugs for cancer treatment are developed via Degronimid platform.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Sonoma Biotherapeutics
Frequently Asked Questions about Sonoma Biotherapeutics
When was Sonoma Biotherapeutics founded?
Sonoma Biotherapeutics was founded in 2012 and raised its 1st funding round 8 years after it was founded.
Where is Sonoma Biotherapeutics located?
Sonoma Biotherapeutics is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.
Is Sonoma Biotherapeutics a funded company?
Sonoma Biotherapeutics is a funded company, having raised a total of $335M across 3 funding rounds to date. The company's 1st funding round was a Series A of $40M, raised on Feb 06, 2020.
How many employees does Sonoma Biotherapeutics have?
As of Dec 31, 2021, the latest employee count at Sonoma Biotherapeutics is 74.
What does Sonoma Biotherapeutics do?
Sonoma Biotherapeutics was established in 2012 in San Francisco, United States, within the biotechnology sector. Regulated T-cell therapies are being advanced by the company to target autoimmune conditions including rheumatoid arthritis, multiple sclerosis, and inflammatory bowel disease, alongside degenerative disorders. Operations center on therapeutic development for these areas. Key figures such as co-founders Fred Ramsdell as CSO, Qizhi Tang, and Alexander Rudensky guide the efforts.
Who are the top competitors of Sonoma Biotherapeutics?
Sonoma Biotherapeutics's top competitors include Moderna, Jazz Pharmaceuticals and C4 Therapeutics.
What products or services does Sonoma Biotherapeutics offer?
Sonoma Biotherapeutics offers Living Cell Therapies and T reg Therapy.
Who are Sonoma Biotherapeutics's investors?
Sonoma Biotherapeutics has 22 investors. Key investors include Fidelity Investments, Lyell Immunopharma, ARE, Mirae Asset, and Janus Henderson Investors.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.